Antibody drugs make use of the body’s own immune system to locate and eliminate cells which are responsible for the target disease. Antibody drugs have been successful in attracting the attention of researchers worldwide owing to their characteristic features such as fewer side effects and high efficacy in curing certain diseases which were previously untreatable.
Download exclusive Sample of this report:
Large scale research development is being conducted in the field of antibody drugs for the past two decades. By 2009, approximately 30 new antibody drugs were launched in the market. With an intention of launching new blockbuster drugs and to reform the pharmaceuticals industry, large pharmaceutical companies have begun to undertake aggressive steps to enter this market. Hence, it is expected that the antibody drugs segment will experience impressive growth in the global pharmaceuticals market.
Antibody drugs show promising efficacy for the treatment of certain diseases for which no equally effective treatment is available. Antibody drugs are primarily used for the treatment of diseases such as central nervous system ailments, allergic diseases, cancer, and infections. Globally, North America is viewed as the largest market for antibody drugs followed by Europe. However, infrastructural development in the healthcare system and growth in awareness regarding the treatment of chronic diseases may influence a rapid growth of this market in Asia and in other parts of the world.
View exclusive Global strategic Business report :
Some of the market players in the antibody drugs industry are Abbott Laboratories, AstraZeneca, Bayer Ag, Genmab, Eli Lilly, Novartis, Merck KGaA, Daiichi Sankyo, Biogen Idec, some and others.
This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include:
- North America
- Asia Pacific
- Rest of the World